PedAM
Pediatric Disease Annotations & Medicines
| Disease | portal hypertension |
| Phenotype | |cirrhosis |
| Sentences | 166 |
| PubMedID- 25649410 | The peripheral arterial vasodilation theory is the most widely accepted explanation for the pathophysiology of hrs (figure 1) [1], which proposes that splanchnic vasodilation that occurs as a consequence of portal hypertension with cirrhosis is the inciting factor for the development of hrs. |
| PubMedID- 25933224 | Liver cirrhosis with portal hypertension is characterized by systemic and splanchnic vasodilatory substances release, especially nitric oxide (no) and prostacyclin [3], which lead to hyperdynamic circulatory status, and further increased mesenteric blood flow and portal inflow. |
| PubMedID- 26240773 | He had uncomplicated child-pugh class a cirrhosis with no history of portal hypertension. |
| PubMedID- 25812120 | In some patients liver fibrosis leads to liver cirrhosis with portal hypertension, hepatocellular dysfunction and increased risk of hepatocellular carcinoma [2,3]. |
| PubMedID- 25657603 | Progressive cirrhosis, with portal hypertension, is characterized by the development of portosystemic shunts and inadequately cleared circulating vasoactive substances eg, nitric oxide, vasoactive intestinal peptide, endocannabinoids, and bile salts, which create a state of splanchnic and arterial vasodilation, leading to ineffective central blood volume, initially compensated by high cardiac output.3,8 with worsening cirrhosis, systemic vascular resistance continues to fall, but cardiac compensation reaches a maximum. |
| PubMedID- 23586850 | Reported a 29% in-hospital mortality after colorectal surgery among patients with liver cirrhosis complicated by portal hypertension and 14% in patients with compensated liver cirrhosis [10]. |
| PubMedID- 26378453 | We investigated the relationship between copeptin and hemodynamic characteristics in an animal model bearing strong resemblance to human cirrhosis, including typical features of portal hypertension and the hyperdynamic circulation, but with a normal kidney function as shown previously [17] and without the use of therapeutic interventions which may affect copeptin levels. |
| PubMedID- 24436365 | Main outcome measurements: (1) incidence of cholestasis, (2) identification of risk factors for cholestasis, (3) association between the presence of cholestasis and mi and the development of clinically significant cf-associated liver disease (cfld) defined as multilobular cirrhosis with portal hypertension. |
| PubMedID- 25454305 | Portal vein thrombosis (pvt) is a rare event in the general medical setting that commonly complicates cirrhosis with portal hypertension, and can also occur with liver tumors. |
| PubMedID- 25789194 | Her liver disease progressed to cirrhosis and was complicated by portal hypertension, refractory ascites, and recurrent episodes of sbp. |
| PubMedID- 25793622 | Blockade of nitric oxide during perfusion of the hepatic arteries in cirrhosis with portal hypertension corrects the vasoconstrictive response to normal. |
| PubMedID- 23787475 | Oct is a somatostatin analogue that has few side effects, and its injection is clinically used for lowering the portal hypertension associated with liver cirrhosis [5]. |
| PubMedID- 22848732 | Diagnosis of cfld is challenging because its clinical presentation ranges from simple steatosis to multi-lobular biliary cirrhosis with portal hypertension [2], [3]. |
| PubMedID- 20113491 | In addition, although splenomegaly should be expected in severe cirrhosis with portal hypertension, there were no statistical differences in splenic area among the three groups analyzed, indicating that splenomegaly was not a prominent feature in our study of cirrhotic rats. |
| PubMedID- 22558526 | He had cirrhosis and thrombocytopenia with portal hypertension, possibly secondary to alcohol use. |
| PubMedID- 24775062 | Myeloproliferative disorder, liver cirrhosis with portal hypertension, deficiency of natural anticoagulant proteins such as protein c or atiii as well as hepatocellular carcinoma are the most frequent causes of portal vein thrombosis [1]. |
| PubMedID- 23593273 | Indeed, a small clinical study evaluating the therapeutic potential of int-747 in regulating portal hypertension in patients with alcoholic cirrhosis has just completed (http://www.ukctg.nihr.ac.uk/trialdetails/isrctn22662520). |
| PubMedID- 26064107 | They can detect advanced cirrhosis with signs of portal hypertension (enlarged spleen and portal vein, and collateral venous circulation), but not fibrosis of lesser stages [76, 77]. |
| PubMedID- 23984413 | Spleen stiffness, but not liver stiffness, was positively correlated with the presence of ascites as a representative marker of portal hypertension in patients with liver cirrhosis and the spleen stiffness did not correlate with the presence of esophageal varices in chronic hepatitis c patients. |
| PubMedID- 21831314 | Sixty-seven patients were not enrolled in the study for the following reasons: (1)cirrhosis and evidence of portal hypertension (n = 17); (2) declined staging procedures and preferred to wait for new hcv therapies (n = 15); (3) omission of survey completion during early months on study implementation (n = 13); (4) declined any medical treatment or evaluation (n = 9); (5) hcv antibody positive and hcv rna negative and did not need hcv therapy (n = 7); and (6) transferring care to a different city and clinical staging could not be completed (n = 6). |
| PubMedID- 23812828 | Histopathological evaluation remains critical in excluding cirrhosis and other causes of portal hypertension, and is the only way of definitively establishing the diagnosis of opv. |
| PubMedID- 23293387 | Characteristically, there is worsening cholestasis, fibrosis and cirrhosis which lead to portal hypertension and a decrease in synthetic function. |
| PubMedID- 23056756 | Liver involvement might progress toward the cirrhosis, accompanied with portal hypertension, ascites and esophageal varicosities, but these manifestations were otherwise mainly absent in our group[5, 7, 10, 20]. |
| PubMedID- 26370856 | Hypothyroidism enhanced portal hypertension in a patient with alcoholic liver cirrhosis, resulting in the development of ascites. |
| PubMedID- 25892988 | This study aimed to further investigate portal venous remodeling in the pathogenesis of liver cirrhosis with portal hypertension, thereby guiding its prevention and treatment. |
| PubMedID- 22009385 | Background: portal hypertension associated with liver cirrhosis increases the risk of postoperative complications after liver resection for hepatocellular carcinoma (hcc). |
| PubMedID- 21506350 | An analysis of 115 liver cirrhosis patients with portal hypertension was made to find out which of them had variceal bleeding and high risk of its development. |
| PubMedID- 24851522 | Aim: cirrhosis with portal hypertension (pht) may be associated with increased small intestinal permeability (sip), predisposing to malnutrition and bacterial translocation causing septicaemia, endotoxaemia and spontaneous bacterial peritonitis. |
| PubMedID- 23329943 | The diagnosis of cirrhosis with portal hypertension was based on a combination of clinical data such as jaundice, ascites, muscle wasting, cutaneous spider angiomas, ecchymosis, palmar erythema and flapping tremors; laboratory data such as decreased serum albumin and prolonged prothrombin time; and us findings such as coarsened echo texture and irregular liver surface. |
| PubMedID- 20814511 | Surgical intervention in cirrhosis of liver with portal hypertension is associated with increased morbidity and mortality. |
| PubMedID- 23559324 | Olt was performed at the age of 7 years, due to liver cirrhosis with portal hypertension, in the absence of neurological lesions and an almost-normal brain mri. |
| PubMedID- 26412302 | Additionally, neo-angiogenesis has been identified as a key mechanism in the progression of liver cirrhosis with portal hypertension3. |
| PubMedID- 25338529 | In the early stages of liver fibrosis, low ho-1 induction may exert a protective action (45), but in the end stages of cirrhosis with portal hypertension, excessive ho-1 expression deteriorates liver function and aggravates liver cirrhosis (43,46,47). |
| PubMedID- 21213113 | Background: in patients with cirrhosis the onset of clinically significant portal hypertension (csph; i.e., hepatic venous pressure gradient (hvpg) >/= 10 mmhg) is associated with an increased risk of complications. |
| PubMedID- 24339715 | Severe chronic illness included liver cirrhosis with portal hypertension, new york heart association class iv congestive heart failure, chronic respiratory disease, end-stage renal disease, or an immune-compromised state (e.g., leukemia, lymphoma, or aids). |
| PubMedID- 24748895 | Meanwhile, a clinical trial demonstrated that prophylactic use of ppis did not improve the portal hypertension-related bleeding in patients with cirrhosis (41). |
| PubMedID- 25539572 | Most portal hypertension results from cirrhosis but extra hepatic portal vein obstruction is the single commonest cause. |
| PubMedID- 23251280 | The patients all suffered from hepatic cirrhosis decompensation with portal hypertension. |
| PubMedID- 23983486 | His medical history was significant for alcoholic cirrhosis with portal hypertension, splenomegaly, hypersplenism, and ascites. |
| PubMedID- 24719556 | Background: oxidative stress is involved in the hypocontractility of visceral artery to vasoconstrictors and formation of hyperdynamic circulation in cirrhosis with portal hypertension. |
| PubMedID- 24171010 | Table 1 summarizes the hepatobiliary clinical findings in cf.the evolution of cfld is usually slow and progressive: only about 10% of patients affected by cf and cirrhosis with portal hypertension progress to liver synthetic failure generally after pediatric age (14, 43, 44). |
| PubMedID- 22034603 | [1] pah is also an uncommon but documented complication of hiv infection, chronic hemolytic anemia, and cirrhosis with portal hypertension. |
| PubMedID- 22121492 | It is this author's opinion that 12 cm should be the threshold to diagnose splenomegaly and raise suspicion of cirrhosis with portal hypertension. |
| PubMedID- 20500867 | • childs b or c cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies or with evidence of moderate to severe ascites. |
| PubMedID- 26406236 | Background & aims: although in cirrhosis with portal hypertension levels of the vasoconstrictor angiotensin ii are increased, this is accompanied by increased production of angiotensin (ang)-(1-7), the endogenous ligand of the mas receptor (masr), which blunts hepatic fibrosis and decreases hepatic vascular resistance. |
| PubMedID- 20951924 | This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage. |
| PubMedID- 23755897 | Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. |
| PubMedID- 23997080 | An evaluation revealed hepatic cirrhosis with portal hypertension, secondary to chronic budd-chiari syndrome. |
| PubMedID- 24673975 | Thrombocytopenia: in time, liver cirrhosis leads to portal hypertension. |
| PubMedID- 24678881 | Clinical studies showed that the markers bgm, elastin mmp-generated neo-epitope fragment (elm) c1m, c3m, c4m c5m, collagen type vi mmp-generated neo-epitope fragment (c6m), pro-c3 and p4np 7s were associated with portal hypertension in patients with cirrhosis, reflecting the degree of liver dysfunction[123]. |